vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit
Company profile
Ticker
BRNS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vaccitech Ltd, Vaccitech plc
SEC CIK
Corporate docs
Subsidiaries
Barinthus Biotherapeutics Pty Limited • Vaccitech Oncology Limited • Barinthus Biotherapeutics (UK) Limited • Barinthus Biotherapeutics North America, Inc. • Barinthus Biotherapeutics Italia S.R.L. • Barinthus Biotherapeutics Switzerland GmbH ...
BRNS stock data
Latest filings (excl ownership)
8-K
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
20 Mar 24
8-K
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
5 Jan 24
8-K
New partnership aims to advance vaccine against MERS coronavirus
22 Dec 23
8-K
Regulation FD Disclosure
9 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.31 mm | 160.31 mm | 160.31 mm | 160.31 mm | 160.31 mm | 160.31 mm |
Cash burn (monthly) | 4.24 mm | 3.32 mm | 5.37 mm | 7.42 mm | 3.73 mm | 3.56 mm |
Cash used (since last report) | 28.32 mm | 22.15 mm | 35.85 mm | 49.54 mm | 24.91 mm | 23.74 mm |
Cash remaining | 131.99 mm | 138.16 mm | 124.46 mm | 110.77 mm | 135.40 mm | 136.56 mm |
Runway (months of cash) | 31.1 | 41.7 | 23.2 | 14.9 | 36.3 | 38.4 |
Institutional ownership, Q2 2022
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 2.69 bn |
Total shares | 4.78 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SC CHINA HOLDING | 1.42 mm | $6.32 mm |
M&G Investment Management | 1.09 mm | $4.35 mm |
DC Funds | 642.20 k | $2.86 mm |
Liontrust Investment Partners | 600.00 k | $2.67 bn |
BlueCrest Capital Management | 542.67 k | $2.42 mm |
Tudor Investment Corp Et Al | 266.93 k | $1.19 mm |
Johns Hopkins University | 107.97 k | $480.00 k |
Millennium Management | 61.40 k | $273.00 k |
Ipswich Investment Management | 39.98 k | $178.00 k |
MS Morgan Stanley | 13.81 k | $61.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Gemma Brown | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.7 | 193,000 | 714.10 k | 193,000 |
2 Jan 24 | William Enright | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.7 | 443,981 | 1.64 mm | 443,981 |
2 Jan 24 | Graham Griffiths | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.7 | 96,500 | 357.05 k | 96,500 |
2 Jan 24 | Nadege Pelletier | Share Option Ordinary Shares | Grant | Acquire A | No | No | 3.7 | 105,000 | 388.50 k | 105,000 |
26 Jun 23 | Joseph Scheeren | Ordinary Shares | Buy | Acquire P | No | No | 2.44 | 10,000 | 24.40 k | 23,000 |
News
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
19 Apr 24
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
19 Apr 24
Barinthus Bio Reports Topline Data From Phase 1b/2 APOLLO Trial Of VTP-200 In Persistent High-Risk HPV Infections; Primary Safety Endpoint Met; VTP-200 Was Generally Well-Tolerated
18 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 Apr 24